Moreover, it would be of great interest to explore if such a tool could also be used for other lymphomas, for example, the identification of MYC translocations in Burkitt lymphoma, and to establish whether such AI solutions can improve hematological cancer patients’ care. This evidence concerns the gene MYC and lymphoma.